NN Investment Partners Holdings N.V. continued to hold its stake in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) during the first quarter, Holdings Channel reports. The fund owned 499 shares of the biopharmaceutical company’s stock at the end of the first quarter. NN Investment Partners Holdings N.V.’s holdings in Regeneron Pharmaceuticals were worth $193,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. State Street Corp boosted its stake in shares of Regeneron Pharmaceuticals by 2.2% in the fourth quarter. State Street Corp now owns 3,240,549 shares of the biopharmaceutical company’s stock worth $1,189,574,000 after buying an additional 68,675 shares during the last quarter. Artisan Partners Limited Partnership boosted its stake in shares of Regeneron Pharmaceuticals by 6.7% in the fourth quarter. Artisan Partners Limited Partnership now owns 1,891,598 shares of the biopharmaceutical company’s stock worth $694,387,000 after buying an additional 118,896 shares during the last quarter. Loomis Sayles & Co. L P boosted its stake in shares of Regeneron Pharmaceuticals by 49.4% in the fourth quarter. Loomis Sayles & Co. L P now owns 1,715,305 shares of the biopharmaceutical company’s stock worth $629,672,000 after buying an additional 567,188 shares during the last quarter. Polen Capital Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 65.2% in the fourth quarter. Polen Capital Management LLC now owns 1,340,649 shares of the biopharmaceutical company’s stock worth $492,139,000 after buying an additional 529,348 shares during the last quarter. Finally, Franklin Resources Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 16.3% in the fourth quarter. Franklin Resources Inc. now owns 911,627 shares of the biopharmaceutical company’s stock worth $334,662,000 after buying an additional 127,891 shares during the last quarter. Hedge funds and other institutional investors own 68.83% of the company’s stock.

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Regeneron Pharmaceuticals Inc (NASDAQ REGN) traded down 0.02% on Monday, reaching $480.31. 239,499 shares of the company’s stock were exchanged. The stock’s 50 day moving average is $422.52 and its 200 day moving average is $386.91. The company has a market cap of $50.71 billion, a price-to-earnings ratio of 58.14 and a beta of 1.44. Regeneron Pharmaceuticals Inc has a 52 week low of $325.35 and a 52 week high of $489.00.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported $2.92 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.50 by $0.42. The company had revenue of $1.32 billion for the quarter, compared to analysts’ expectations of $1.30 billion. Regeneron Pharmaceuticals had a return on equity of 22.51% and a net margin of 18.10%. The business’s quarterly revenue was up 9.8% compared to the same quarter last year. During the same period in the previous year, the business posted $2.57 earnings per share. On average, equities analysts anticipate that Regeneron Pharmaceuticals Inc will post $12.66 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This report was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at https://www.watchlistnews.com/regeneron-pharmaceuticals-inc-regn-stake-held-by-nn-investment-partners-holdings-n-v/1334524.html.

A number of analysts have recently weighed in on REGN shares. Vetr upgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $475.44 price objective for the company in a research note on Wednesday, March 15th. BMO Capital Markets restated a “hold” rating and issued a $412.00 price objective (up from $408.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, March 28th. Leerink Swann restated an “outperform” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, March 20th. Canaccord Genuity upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $375.00 to $484.00 in a research note on Friday, May 5th. Finally, Zacks Investment Research upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $416.00 price objective for the company in a research note on Thursday, April 27th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and twelve have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $432.21.

In other news, Director Michael S. Brown sold 1,000 shares of the business’s stock in a transaction dated Wednesday, March 29th. The stock was sold at an average price of $400.00, for a total transaction of $400,000.00. Following the sale, the director now directly owns 1,000 shares in the company, valued at $400,000. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Chairman P Roy Vagelos sold 9,295 shares of the business’s stock in a transaction dated Thursday, May 25th. The stock was sold at an average price of $458.14, for a total value of $4,258,411.30. Following the sale, the chairman now owns 414,156 shares in the company, valued at $189,741,429.84. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 13,295 shares of company stock worth $6,008,411. Company insiders own 10.40% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Receive News & Ratings for Regeneron Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.